Table 1.

Demographic data of all patients that are part of the German MS registry or of the REGIMS registry and have received daclizumab including 95% confidence intervals for the mean, resp. Clopper-Pearson variants for proportions.

	First line daclizumab GMSR	Second line daclizumab GMSR	Third line daclizumab GMSR	Fourth line and later daclizumab GMSR	GMSR	REGIMS
N	59	67	54	65	245	22
Age in 2018, mean	41.8 [38.6–45.0]	41.8 [39.1–44.4]	44.0 [40.8–47.1]	43.7 [41.3–46.0]	42.8 [41.4–44.2]	40.9 [36.8–45.0]
Age onset, mean	31.3 [28.5–34.2]	31.4 [28.9–34.0]	30.3 [27.6–33.1]	28.0 [26.1–29.9]	30.2 [29.0–31.5]	30.4 [26.6–34.2]
Time to diagnosis (years), mean	2.0 [0.5–3.5]	1.1 [0.4–1.7]	3.2 [1.8–4.7]	1.3 [0.4–2.2]	1.9 [1.3–2.5]	1.9 [0.6–3.2]
Disease duration, mean	8.6 [6.1–11.1]	9.3 [7.5–11.0]	12.4 [10.4–14.4]	14.5 [12.6–16.3]	11.3 [10.2–12.3]	8.6 [5.6–11.6]
Treatment dur. (years), mean	0.85 [0.75–0.95]	0.80 [0.70–0.89]	0.79 [0.70–0.88]	0.84 [0.75–0.94]	0.82 [0.77–0.87]	0.89 [0.72–1.06]
Female (%)	67.8% [54.4–79.4]	71.6% [59.3–82.0]	77.8% [11.0–12.0]	80.0% [68.2–88.9]	74.2% [68.3–79.6]	68.2% [45.1,86.1]
Severity
Mild       [EDSS 0.0–2.5]	60.3% [46.6–73.0]	54.8% [41.7–67.5]	44.0% [30.0–58.7]	43.3% [30.6–56.8]	50.9% [44.2–57.5]	61.9% [38.4–81.9]
Moderate       [EDSS 3.0–5.5]	22.4% [12.5–35.3]	41.9% [29.5–55.2]	50.0% [35.5–64.5]	41.7% [29.1–55.1]	38.7% [32.4–45.3]	28.6% [11.3–52.2]
Severe       [EDSS 6.0–9.5]	17.2% [8.6–29.4]	3.2% [0.4–11.2]	6.0% [1.3–16.5]	15.0% [7.1–26.6]	10.4% [6.8–15.1]	9.5% [1.2–30.4]
EDSS, mean	2.56 [1.97–3.15]	2.58 [2.14–3.02]	2.88 [2.46–3.30]	3.26 [2.79–3.74]	2.82 [2.57–3.06]	2.97 [2.29–3.65]